1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Medicenna Therapeutics Corp.
  6. News
  7. Summary
    MDNA   CA58490H1073

MEDICENNA THERAPEUTICS CORP.

(MDNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medicenna Therapeutics Corp. Announces Management Change and Appoints Experienced Development Advisory Committee

01/17/2022 | 06:00pm EDT

Medicenna Therapeutics Corp. announced that Mann Muhsin has resigned as Chief Medical Officer of the company to assume a position closer to home. Martin Bexon who has managed many aspects of Medicenna’s clinical programs since 2016, will serve as Acting Chief Medical Officer in addition to his current role as the Medical Monitor for the Phase 1/2 ABILITY study. Medicenna also announced the appointment of industry veterans to its Development Advisory Committee. Dr. Martin Bexon has worked as a strategic adviser, study medical expert, and medical monitor in a number of oncology programs in both solid tumors and hematological malignancies. While at CSL Behring (Bern, Switzerland), he led multiple global clinical studies across a range of indications. At Hoffman-La Roche (U.K. and Switzerland), Martin designed and executed multiple global clinical trials enrolling more than 10,000 subjects to support product commercialization. Mr. Paul Smith, Dr. Bruce Pearce and Dr. Peter Lloyd, who have been instrumental in supporting MDNA11’s pre-clinical safety, PK/PD studies, international regulatory filings and designing the ABILITY study. Paul Smith brings 25 years of global regulatory experience with a focus on oncology. He has held positions of increasing responsibilities during his 20-year tenure at Amgen before joining Tusk Therapeutics (an immuno-oncology company targeting the IL-2 CD25 receptor) as VP of Regulatory Affairs until its acquisition by Roche and more recently has been guiding Medicenna’s global regulatory submissions and strategy for MDNA11. Dr. Peter Lloyd, PhD, has more than 25 years of drug development experience, mostly at Novartis. His expertise spans PK/PD models, immunogenicity assessment and exposure response relationships with both small molecule and biologics. He was formerly the Head of DM/PK Biologics at Novartis and has been the key contributor to MDNA11’s PK studies and PK modeling.


ę S&P Capital IQ 2022
All news about MEDICENNA THERAPEUTICS CORP.
05/11Medicenna Presents Phase 1/2 ABILITY Data Highlighting MDNA11's "Favorable" Clinical Pr..
MT
05/11Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11'..
CI
05/11Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinica..
AQ
05/02Medicenna up 7.3% in US Pre-Market as Details Promising New Clinical Data From Phase 1/..
MT
05/02MEDICENNA THERAPEUTICS : Announces New Clinical Data Showing Dose-Dependent Stimulation of..
PU
05/02Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer..
AQ
05/02Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimula..
CI
04/27MEDICENNA THERAPEUTICS : to Present at the 2022 Bloom Burton & Co. Healthcare Investor Con..
PU
04/27Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Co..
AQ
04/08Medicenna Presents Preclinical Data Showing Anti-Cancer Activity at the AACR Annual Mee..
MT
More news
Analyst Recommendations on MEDICENNA THERAPEUTICS CORP.
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -25,1 M -19,4 M -19,4 M
Net Debt 2022 - - -
P/E ratio 2022 -3,08x
Yield 2022 -
Capitalization 79,5 M 61,5 M 61,5 M
Capi. / Sales 2022 -
Capi. / Sales 2023 55,3x
Nbr of Employees 13
Free-Float 66,9%
Chart MEDICENNA THERAPEUTICS CORP.
Duration : Period :
Medicenna Therapeutics Corp. Technical Analysis Chart | MDNA | CA58490H1073 | MarketScreener
Technical analysis trends MEDICENNA THERAPEUTICS CORP.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,43 CAD
Average target price 11,48 CAD
Spread / Average Target 702%
EPS Revisions
Managers and Directors
Fahar Merchant Chairman, President & Chief Executive Officer
Elizabeth Williams Chief Financial Officer & Secretary
Martin Bexon Chief Medical Officer
Albert George Beraldo Independent Non-Executive Director
Chandrakant J. Panchal Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDICENNA THERAPEUTICS CORP.-31.90%61
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153